Microcap Ledger Azitra, Inc. $AZTR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Branford, CT
- Fiscal year end
- December 31
- Shares outstanding
- 60,603,742 [10-Q 2026-08-12]
What the company doesAI summary of filing
Azitra, Inc. is an early-stage clinical biopharmaceutical company developing topical live biotherapeutic products and engineered proteins for dermatological diseases. The company has built a proprietary platform consisting of a microbial library of approximately 1,500 unique bacterial strains, artificial intelligence and machine learning technology to screen strains, and a licensed genetic engineering technology. Azitra has not commenced commercial operations and is currently advancing two lead programs, ATR-12 and ATR-04, through clinical trials, with ATR-12 in Phase 1b trials for Netherton syndrome (first patient dosed August 2024) and ATR-04 in Phase 1/2 trials for EGFR inhibitor-associated rash (first patient dosed third quarter 2025). [10-K 2026-02-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$7.27M | −$5.77M | $6.73M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $0.00 | −$10.96M | −$11.22M | $2.07M | [10-K 2026-02-27] |
| FY ended Dec 2024 | $7.5K | −$8.97M | −$10.18M | $4.55M | [10-K 2026-02-27] |
- Quarterly cash burn
- −$2.88M
- Cash runway Estimate
- ~7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 7,626,056 | [10-Q 2024-11-12] |
| 2025-02-24 | 14,979,354 | [10-K 2025-02-24] |
| 2025-05-13 | 16,476,354 | [10-Q 2025-05-13] |
| 2025-08-11 | 23,476,354 | [10-Q 2025-08-11] |
| 2025-11-11 | 10,204,938 | [10-Q 2025-11-12] |
| 2026-02-26 | 16,192,438 | [10-K 2026-02-27] |
| 2026-05-11 | 16,192,438 | [10-Q 2026-05-13] |
| 2026-08-11 | 60,603,742 | [10-Q 2026-08-12] |
- Shelf registration
- S-1 filed 2026-05-21; declared effective 2026-06-02 [S-1 2026-05-21]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-03-13. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-03-13 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-13] |
| 2025-12-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-12-17] |
| 2025-10-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-03] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-16 | Salva Francisco D. | other | 4,064,050 | — | [4 2026-06-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-01 | 8-K | Other events |
| 2026-09-28 | 8-K | Material agreement entered |
| 2026-09-28 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-08 | 8-K | Regulation FD disclosure |
| 2026-08-21 | 8-K | Other events |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 8-K | Results of operations |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-07-15 | 8-K | Other events |
| 2026-06-25 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-24 | 13D | Beneficial ownership report (5%+ holder) |
Alerts for $AZTR
Email me when Azitra, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.